Bluebird Bio has seen its share price drop by 25% after the company announced a further delay to the filing of its sickle cell disease gene therapy candidate, lovotibeglogene autotemcel, or lovo-cel.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?